Freeline Therapeutics Holdings PLC (FRLN)
Stock Price:
$16.91 USD
-0.28 (-1.63%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
587.53M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-53.91M |
| Shares Out |
34.74M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 18, 2020 |
| Last Price |
$16.91 |
| Previous Close |
$17.19 |
| Change ($) |
-0.28 |
| Change (%) |
-1.63% |
| Day's Open |
17.45 |
| Day's Range |
16.30 - 18.00 |
| Day's Volume |
145,272 |
| 52-Week Range |
15.25 - 21.69 |
More Stats
| Market Cap |
587.53M |
| Enterprise Value |
513.83M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
34.74M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-8.71 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.15M |
| Short Ratio |
1.63 |
| Short % of Float |
0.00% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
7.03 |
| Revenue |
n/a |
| Operating Income |
-63.64M |
| Net Income |
-53.91M |
| Free Cash Flow |
-55.30M |
| Net Cash |
73.70M |
| Net Cash / Share |
2.12 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-51.20% |
| ROE |
-99.90% |
| ROIC |
-595.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$28.75*
(70.02% upside)
Low
27.0
Current: $16.91
High
32.0
Target: 28.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -63.64 | -40.98 |
| Net Income | -53.91 | -33.28 |
| Shares Outstanding | 6.35 | 4.62 |
| Earnings Per Share | -8.49 | -7.20 |
| Operating Cash Flow | -52.32 | -25.77 |
| Capital Expenditures | -2.98 | -3.71 |
| Free Cash Flow | -55.30 | -29.49 |
| Cash & Equivalents | 73.70 | 16.05 |
| Net Cash / Debt | 73.70 | 16.05 |
| Assets | 97.39 | 32.13 |
| Liabilities | 12.43 | 9.16 |
| Book Value | 84.96 | 22.97 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Freeline Therapeutics Holdings PLC |
| Country |
United Kingdom |
| Employees |
200 |
| CEO |
Theresa Heggie |
Stock Information
| Ticker Symbol |
FRLN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FRLN |
| IPO Date |
August 7, 2020 |
Description
Freeline Therapeutics Holdings plc operates as a clinical-stage systemic adeno-associated virus (AAV)-based gene therapy company. Its advanced product candidate is FLT180a, a gene therapy product candidate that is being evaluated in a Phase 1/2 dose-finding clinical trials in adult males for the treatment of patients with moderate or severe hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Address: Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX